

Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/clinical-practice/cardiology/cetp-inhibition-and-obicetrapib-a-new-era-in-lipid-management/37123/>

ReachMD

www.reachmd.com
info@reachmd.com
(866) 423-7849

CETP Inhibition and Obicetrapib: A New Era in Lipid Management

Announcer:

Welcome to DataPulse from ESC 2025 on ReachMD. This activity, titled "C-E-T-P Inhibition and Obicetrapib: A New Era in Lipid Management" is provided by Medcon International.

Dr. Ray:

Hello, my name is Kausik Ray. I'm professor of public health at Imperial College London, and I'm here at ESC 2025, and the obvious news here is the update on the lipid guidelines. And what we've seen change is now a greater acceptance of combination therapies and the recognition that, particularly for the high- and very-high-risk patients, that those goals are not going to be achievable with statin-based monotherapy.

Statins will remain the background and be baseline therapy that we need. However, we clearly need more and more patients on a second or a third drug. And we've seen a lot of presentations about the addition of different therapies. And amongst those, in the future, might be obicetrapib as an add-on therapy that gives you 35% lowering of LDL cholesterol, 20% lowering of APOB, and 30% reduction in non-HDL cholesterol.

It's still an investigational drug. However, it's clear that even when we use statins and ezetimibe, roughly 40% to 50% of patients may get to goal. Amongst other patients, it might be 65% of patients. But that still leaves a substantial group of patients not at goal.

Obicetrapib has a unique property: one, which is the LDL lowering, but also the LPA lowering. And although we didn't specifically test populations thus far with very high LPA, the role of LPA testing that's come out at ECA and the importance of this, is a group of individuals who have higher residual risk because LPA is high and they might not meet the eligibility criteria for newer emerging therapies. So clearly an LDL-lowering therapy that lowers both LDL and LPA and helps patients get to their primary target, the LDL goal, is going to be attractive. So it's a really bright future and we're all excited about the PREVAIL trial that will report in the future to see if the addition of obicetrapib will reduce cardiovascular events as well.

Thank you for listening.

Announcer:

Thank you for listening to this DataPulse from ESC 2025 on ReachMD. This activity is provided by Medcon International. Thank you for listening.